Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Outpatient management of CAR-T therapy in multiple myeloma and lymphoma

Radhika Bansal • 9 Dec 2023
ASH 2023
Lymphoma Multiple Myeloma Antibodies CAR-T Tocilizumab

Radhika Bansal, MBBS, Mayo Clinic, Rochester, MN, explores the feasibility of hospital-based outpatient (HBO) management post-CAR-T therapy for patients with multiple myeloma (MM) and lymphoma. She highlights remote patient monitoring, outpatient management of cytokine release syndrome (CRS) with tocilizumab, and the incorporation of home visits by community paramedics. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Radhika Bansal

1:49
Outpatient management of patients with multiple myeloma treated with bispecific antibodies
Radhika Bansal • 9 Dec 2023
2:00
Prognostic tool to identify CAR-T outcomes in patients with aggressive lymphoma
Radhika Bansal • 11 Dec 2022
2:23
Prophylactic dexamethasone use with CAR-T therapy: real-world practice and outcomes
Radhika Bansal • 11 Dec 2022
1:26
Feasibility and safety of outpatient practice for recently approved CAR-T therapies
Radhika Bansal • 11 Dec 2022

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals